Erasca Inc. (NASDAQ:ERAS) is one of the 11 Stocks With 3x-5x Returns This Year.

Erasca has seen its share prices soar by 390 percent year-to-date, as investors sought to increase their exposure in the company amid developments on its treatment candidate for solid tumors.

Earlier in the year, Erasca Inc. (NASDAQ:ERAS) expanded its worldwide rights to develop and commercialize its treatment candidate, ERAS-0015—which has a best-in-class potential—to China, Hong Kong, and Macau, sparking revenue growth opportunities in the said areas.

Photo by Pietro Jeng on Pexels

In addition, it inked a collaboration and supply agreement with Tango Therapeutics Inc. to evaluate the efficacy of ERAS-0015 when combined with the latter’s PRMT5 inhibitor, vopimetostat (TNG462).

The combination represents a promising opportunity to redefine the standard of care in patients with MTAP-deleted RAS-mutant (MTAPdel RASm) cancers, where treatment options remain limited, Erasca Inc. (NASDAQ:ERAS) said.

The company is targeting to report the results of its clinical trial for ERAS-0015 in the first half of the year, as well as for its pan-KRAS inhibitor, ERAS-4001, in the second half of the year.

ERAS-4001 is an oral, highly potent, and selective inhibitor targeting solid tumors with KRAS mutations.

Last year, Erasca Inc. (NASDAQ:ERAS) narrowed its net loss by 22.9 percent to $124.5 million from $161.6 million in 2024. Total operating expenses declined by 21 percent to $140.9 million from $179.5 million year-on-year.

While we acknowledge the potential of ERAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT:  33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .

Disclosure: None. Follow Insider Monkey on Google News .